ArticleDiscover oncology2025
Genomic profiling of AKT1 and NRAS mutations using NGS in Egyptian hepatocellular carcinoma.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesHepatocellular carcinoma (HCC) remains a major health burden in Egypt, with underlying molecular mechanisms still poorly defined. This study aimed to characterize somatic mutations in AKT1 and NRAS genes using targeted next-generation sequencing in Egyptian HCC patients.
methodsCell Tumor DNA (ct DNA) from 50 patients, divided into 25 HCC patients, were classified according to Barcelona clinic Liver Cancer (BCLC) staging alongside HCV-infected and normal controls, was analyzed using the Ion AmpliSeq Cancer Hotspot Panel. Mutational profiles were verified using the Integrative Genomics Viewer and functionally annotated via different cancer databases.
resultsA total of 16 somatic mutations were identified (12 in AKT1, 4 in NRAS). The most frequent AKT1 mutation was p.Asp32Glu, observed in multiple clinical groups. Other variants, including p.Glu40Gly and p.Asn31Ile, affected conserved regions of the kinase domain. AKT1 mutations were more prevalent in intermediate and advanced HCC stages, suggesting a role in tumor progression. In contrast, NRAS mutations were rare and evenly distributed across stages, with limited clinical correlation. Functional predictions supported the potential pathogenicity of several AKT1 and NRAS variants.
conclusionThis study highlights a higher frequency and diversity of AKT1 mutations in Egyptian HCC patients, particularly in progressive disease stages, supporting their potential role in HCC development and progression. These findings advocate for expanded molecular profiling in HCC and suggest AKT1 as a promising target for personalized therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.